Torskal Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2.22M

  • Investors
  • 5

Torskal General Information

Description

Operator of a biotech company intended to design disruptive gold nanoparticles for cancer therapy using green chemistry. The company uses green nanotechnology for the development of non-toxic and eco-friendly nanomaterials for the treatment of surface and deep cancers, enabling healthcare providers to cure their patients with non-toxic, and eco-friendly cancer therapies that target both surface and deep cancers that promotes treatment outcomes while reducing harmful side effects.

Contact Information

Website
www.torskal.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2 rue Maxime Rivière
  • Sainte Clotilde
  • 97490
  • France
+33 02
Primary Industry
Specialty Chemicals
Corporate Office
  • 2 rue Maxime Rivière
  • Sainte Clotilde
  • 97490
  • France
+33 02

Torskal Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Torskal Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 02-Feb-2026 $2.22M Completed Pre-Clinical Trials
7. Seed Round 13-Feb-2025 Completed Pre-Clinical Trials
6. Seed Round 31-Dec-2020 Completed Pre-Clinical Trials
5. Accelerator/Incubator 23-Jun-2017 Completed Clinical Trials - Phase 1
4. Grant 31-Dec-2016 Completed Clinical Trials - Phase 1
3. Grant Completed Clinical Trials - Phase 1
2. Accelerator/Incubator Completed Clinical Trials - Phase 1
1. Accelerator/Incubator Completed Clinical Trials - Phase 1
To view Torskal’s complete valuation and funding history, request access »

Torskal Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary Shares
Ordinary Shares
Ordinary Shares
Ordinary Shares 123 $82.157535 $714.5 $714.5 1x $714.5 1.07%
Ordinary Shares 399 $82.157535 $664.3 $664.3 1x $664.3 3.48%
To view Torskal’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Torskal Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotech company intended to design disruptive gold nanoparticles for cancer therapy using green chemistry.
Specialty Chemicals
France
3 As of 2026

Houston, TX
 

Paris, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Torskal Competitors (2)

One of Torskal’s 2 competitors is Nanospectra, a Venture Capital-Backed company based in Houston, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nanospectra Venture Capital-Backed Houston, TX
Nanobiotix Formerly VC-backed Paris, France
You’re viewing 2 of 2 competitors. Get the full list »

Torskal Patents

Torskal Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3164393-A1 Plasmon photothermal treatment of skin cancers with extensive lesions using gold nanoparticles Pending 10-Jul-2024
FR-3131850-A1 Ultrasonic-assisted synthesis of nanoparticles consisting of a gold-covered ferric core Active 20-Jan-2022
FR-3131850-B1 Ultrasound-assisted synthesis of nanoparticles consisting of a gold-coated ferric core Inactive 20-Jan-2022
WO-2022263451-A1 Peptides derived from the spike protein of sars-cov-2 and uses thereof for diagnosis and vaccine purposes Inactive 15-Jun-2021
EP-4313445-A1 Ecologic method for preparing silver nanoparticles from an extract of and uses thereof Inactive 26-Mar-2021 B22F9/24
To view Torskal’s complete patent history, request access »

Torskal Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Torskal Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Clinifutur Corporation Minority
Silicon Valley Advantage Accelerator/Incubator
European Commission Government
Matwin Accelerator/Incubator
The Technopole of Reunion Island Accelerator/Incubator
To view Torskal’s complete investors history, request access »

Torskal FAQs

  • When was Torskal founded?

    Torskal was founded in 2015.

  • Where is Torskal headquartered?

    Torskal is headquartered in France.

  • What is the size of Torskal?

    Torskal has 3 total employees.

  • What industry is Torskal in?

    Torskal’s primary industry is Specialty Chemicals.

  • Is Torskal a private or public company?

    Torskal is a Private company.

  • What is the current valuation of Torskal?

    The current valuation of Torskal is .

  • What is Torskal’s current revenue?

    The current revenue for Torskal is .

  • How much funding has Torskal raised over time?

    Torskal has raised $2.79M.

  • Who are Torskal’s investors?

    Clinifutur, Silicon Valley Advantage, European Commission, Matwin, and The Technopole of Reunion Island have invested in Torskal.

  • Who are Torskal’s competitors?

    Nanospectra and Nanobiotix are competitors of Torskal.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process